Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
|Videos|October 3, 2018
Omadacycline: A Potential Fluoroquinolone Replacement?
Author(s)Contagion® Editorial Staff
Jason Gallagher, PharmD, discusses how omadacycline could potentially replace fluoroquinolone use in the treatment of complicated skin infections and community-acquired pneumonia.
Advertisement
Jason Gallagher, PharmD: Omadacycline is another novel tetracycline that is being developed. This one is pursuing indications for complicated skin infections and for community-acquired pneumonia. Now, as a novel tetracycline, I kind of see it as a potential fluoroquinolone replacement in the treatment of community-acquired pneumonia and some other mixed infections such as the skin and soft tissue infections that have been developed.
With some of the warnings that have come out discouraging fluoroquinolone use for certain indications—warnings from the US Food and Drug Administration that are fairly strong—other options [are limited]. Now, many of those other options when they work, are cheap, inexpensive generic antibiotics that should be used. But for the more resistant infections, where sometimes something else is needed, omadacycline could potentially be an agent that we use, and it should be available orally which would be a significant plus compared with most of the other drugs that have been developed in the past 5 to 6 years.
Advertisement
Related to this article
IDSA/ESCMID panel member Henry Chambers, MD, explains why the new S aureus bacteremia guidance replaces the complicated vs uncomplicated label with risk stratification, and how the statements are akin to the stages of cancer in guiding treatment decisions associated with this bacteremia.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Advertisement
Advertisement
Trending on Contagion Live
1
New IDSA/ESCMID S aureus Bacteremia Consensus Statements: a Risk Stratification Framework
2
On World Rabies Day, When to Seek Treatment, Clinical Considerations for Post Exposure Prophylaxis
3
Further Insights, Treatment Considerations Around the PETERPEN Study
4
VYD2311 Shows Superior Tolerability to mRNA COVID-19 Vaccine in Phase 3 Study
5